Icon (NASDAQ:ICLR) Stock Gets Price Target Boost from TD Cowen

Key Points

• TD Cowen raised ICON’s price target from $197 to $254 and maintained a “buy” rating, implying approximately 16.9% upside from the prior close.
• Analyst sentiment remains positive overall, with ICON carrying a “Moderate Buy” consensus rating and an average price target of $206.35, though ratings include nine “hold” recommendations and one “sell.”
• ICON’s latest quarter modestly exceeded expectations, reporting $2.66 in EPS versus $2.62 expected and $2.02 billion in revenue versus $2.01 billion forecast; however, revenue declined 0.9% year over year and EPS fell from $3.31.

Icon (NASDAQ:ICLR - Get Free Report) had its target price upped by equities research analysts at TD Cowen from $197.00 to $254.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The firm currently has a "buy" rating on the medical research company's stock. TD Cowen's target price would suggest a potential upside of 16.93% from the stock's previous close.

Other analysts have also issued research reports about the stock. Truist Financial lifted their price objective on shares of Icon from $209.00 to $268.00 and gave the stock a "buy" rating in a research report on Thursday. William Blair raised Icon to a "strong-buy" rating in a report on Thursday, July 30th. Citigroup reiterated a "neutral" rating on shares of Icon in a research note on Thursday. Deutsche Bank Aktiengesellschaft reissued a "buy" rating and set a $250.00 price objective on shares of Icon in a report on Thursday. Finally, UBS Group restated a "neutral" rating and issued a $236.00 target price (up from $195.00) on shares of Icon in a research note on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $206.35.

Icon Stock Up 1.4%

NASDAQ:ICLR traded up $3.06 on Thursday, hitting $217.22. The stock had a trading volume of 824,214 shares, compared to its average volume of 1,256,256. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.95 and a current ratio of 0.95. The stock has a market cap of $16.63 billion, a P/E ratio of 51.12, a price-to-earnings-growth ratio of 11.98 and a beta of 1.24. Icon has a 1 year low of $66.57 and a 1 year high of $219.04. The firm's fifty day simple moving average is $170.36 and its two-hundred day simple moving average is $146.19.

Icon (NASDAQ:ICLR - Get Free Report) last announced its earnings results on Tuesday, October 27th. The medical research company reported $2.66 earnings per share for the quarter, topping analysts' consensus estimates of $2.62 by $0.04. The firm had revenue of $2.02 billion for the quarter, compared to the consensus estimate of $2.01 billion. Icon had a return on equity of 8.02% and a net margin of 3.99%. The company's revenue was down .9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.31 EPS. Analysts predict that Icon will post 9.55 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Eugene Mccague sold 3,255 shares of the stock in a transaction dated Thursday, September 17th. The shares were sold at an average price of $175.00, for a total transaction of $569,625.00. Following the sale, the director directly owned 3,811 shares of the company's stock, valued at approximately $666,925. This represents a 46.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Ciaran Murray sold 2,677 shares of the business's stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $164.29, for a total value of $439,804.33. Following the completion of the transaction, the director directly owned 20,452 shares of the company's stock, valued at approximately $3,360,059.08. This trade represents a 11.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 23,068 shares of company stock valued at $3,936,744 over the last 90 days. 44.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Icon

Large investors have recently added to or reduced their stakes in the stock. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Icon in the third quarter valued at about $38,000. Verdence Capital Advisors LLC acquired a new position in Icon during the third quarter worth about $571,000. Pullen Investment Management LLC acquired a new position in Icon during the third quarter worth about $907,000. Gibbs Wealth Management purchased a new stake in Icon during the 3rd quarter valued at about $235,000. Finally, Inspire Investing LLC grew its stake in Icon by 8.4% during the 3rd quarter. Inspire Investing LLC now owns 18,625 shares of the medical research company's stock valued at $3,166,000 after acquiring an additional 1,443 shares in the last quarter. 95.61% of the stock is owned by hedge funds and other institutional investors.

Icon News Summary

Here are the key news stories impacting Icon this week:

• Positive Sentiment: Analyst price-target increase: Robert W. Baird raised its price target from $210 to $249 and maintained an “outperform” rating, implying approximately 15.6% upside from the referenced share price. Robert W. Baird stock recommendations
• Positive Sentiment: Q3 earnings and revenue beat estimates: ICON reported adjusted earnings of $2.66 per share versus the $2.62 consensus estimate, while revenue of $2.02 billion exceeded expectations of $2.01 billion. Management also raised its 2026 guidance. ICON Q3 earnings and revenues beat estimates
• Positive Sentiment: Strong bookings and outlook: Record net bookings of $3.15 billion and a roughly $24.5 billion backlog support management’s expectation for mid-single-digit revenue growth in 2027, improving visibility for future sales. ICON signals 2027 revenue expansion
• Positive Sentiment: Enhanced shareholder returns: ICON redeemed 2.36 million shares and announced an expanded buyback program. The repurchases could support per-share results and signal management confidence in the company’s long-term prospects. ICON completes note issuance and share redemption
• Neutral Sentiment: Debt restructuring: ICON completed a $2.15 billion note issuance and is restructuring its debt. The financing provides liquidity and flexibility for buybacks, but also increases the importance of interest costs and balance-sheet management. ICON restructures debt and expands buybacks
• Negative Sentiment: Valuation and earnings pressure: Revenue declined 0.9% year over year and EPS fell from $3.31 in the prior-year quarter to $2.66. One analysis argues that ICLR could be about 15% overvalued after its recent rally, increasing downside risk if growth or execution disappoints. ICON could be overvalued

About Icon

ICON plc is a global contract research organization that provides outsourced development services to pharmaceutical, biotechnology and medical device companies. The company supports clinical research programs from early development through late-stage trials, regulatory submission and post-marketing activities.

Its services include clinical trial management, medical and regulatory consulting, biostatistics, data management, pharmacovigilance, laboratory services and real-world evidence solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.